期刊文献+

老年人原发性胆汁性肝硬化的临床特征 被引量:9

Clinical features of elderly patients with primary biliary cirrhosis
原文传递
导出
摘要 目的分析老年人原发性胆汁性肝硬化(PBC)的临床、生化、免疫学及病死率等特征。方法对1991年1月至2004年3月期间临床诊断PBC的108例患者进行回顾性分析,比较老年(≥60岁)和中青年患者的一般资料、临床表现、生物化学、免疫学及病死率等特征。结果确诊PBC时,28例老年患者的临床表现和中青年患者相似,老年组男性比例高于中青年组(214%对63%,P<001),老年组和中青年组的血清总胆红素水平分别为(376±265)μmol/L和(647±630)μmol/L(P<005),其他肝功能实验和免疫学指标等差异无显著性。随访期间,老年组肝病相关的死亡率明显高于中青年组(214%对25%,P<001)。结论和中青年患者比较,老年PBC患者肝病相关的死亡更为常见,提示年龄为影响PBC患者预后的一项重要因素。 Objective To evaluate clinical features and mortality of primary biliary cirrhosis (PBC) in the aged patients. Methods Clinical data of 108 patients diagnosed with PBC was reviewed. The diagnosis of PBC was made according to the 2000 practice guidelines of American Association for the study of liver Diseases (AASLD). Elderly patients (≥60 years) were compared in terms of clinical, biochemical, immunological features and mortality with younger patients (<60 years). Results Among the 108 patients, the initial diagnosis of PBC was made in 28 patients at an age ≥60. The elder patients had similar clinical manifestations, except for higher male/female ratio compared with younger patients (6/22 vs 5/75, P<0.01). The serum level of total and direct bilirubin was lower in elderly patients compared with that of younger patients [(37.6±26.5)μmol/L vs (64.7±63.0)μmol/L and (17.5±15.8)μmol/L vs (38.6±43.1)μmol/L, respectively, P<0.05], whereas there were no statistical differences in serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transpeptidase level and immunological findings between older and younger patients (P>0.05). After a median follow-up of 36 months, the mortality ratio for liver diseases was higher in the elderly than in younger group (21.4% vs 2.5%, ~P<0.01). Conclusions Elderly patients have similar clinical manifestations, liver biochemistry and immunological findings, but a higher mortality rate due to related diseases compared with younger patients. This suggests that old age may be an adverse risk factor for the prognosis of PBC.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2005年第1期18-20,共3页 Chinese Journal of Geriatrics
  • 相关文献

参考文献8

  • 1张福奎,贾继东,王宝恩,钱林学,尹珊珊,王宇,崔焱,尤红,马红,王惠吉,张长淮.45例原发性胆汁性肝硬化的临床特征[J].中华内科杂志,2002,41(3):163-167. 被引量:84
  • 2Heathcote EJ. Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines. Hepatology, 2000, 31:1005-1013. 被引量:1
  • 3Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years. Gastroenterology, 2002,123:1044-1051. 被引量:1
  • 4Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology, 1998,28:33-38. 被引量:1
  • 5Newton JL, Jones DE, Metcalf JV, et al. Presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing, 2000,29 : 305-309. 被引量:1
  • 6Poupon RE, Bonnard AM, Chretien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology, 1999, 29:1668-1671. 被引量:1
  • 7Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet, 1999,25:1053-1060. 被引量:1
  • 8Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol,2003,39:142-148. 被引量:1

二级参考文献1

  • 1Dr. T. Maeda MD,S. Onishi MD,T. Miura MD,S. Iwamura MD,A. Tomita MD,T. Saibara MD,Y. Yamamoto MD. Exacerbation of primary biliary cirrhosis during interferon-α2b therapy for chronic active hepatitis C[J] 1995,Digestive Diseases and Sciences(6):1226~1230 被引量:1

共引文献83

同被引文献122

引证文献9

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部